Poseida Therapeutics is a spin out of Transposagen Biopharmaceuticals that utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need.  We have demonstrated proof-of-principle that validates the potential of our differentiated genome engineering technologies and their therapeutic applications.  Our technology platforms have broad applicability and Poseida’s long-term goal is to apply its proprietary gene editing technologies to a broad range of human diseases.  The initial applications of Poseida’s technologies will be in gene therapy and CAR-T product candidates for liver disorders and cancer, respectively.


 

Board Of Directors

Senior Management

Scientific Advisory Board